Pacira Announces Topline Phase 3 Results for Exparel
Pacira recently announced the completion of two Phase 3 placebo-controlled studies evaluating the efficacy, safety, and pharmacokinetics of Exparel (bupivacaine liposome injectable suspension) as a single-dose nerve block for prolonged regional analgesia.
To view the results of the studies, click here.
Recent Posts